Which Biomarkers Does the 2026 Systems Medicine Review Identify for Tracking Semaglutide's Node-Level Response in a Running Protocol?
The 2026 Vitorino and colleagues systems medicine review (Expert Review of Clinical Pharmacology, Tandfonline) identifies distinct biomarker signatures for each of semaglutide's three non-glycaemic pathway nodes: hsCRP and IL-6 for the inflammatory node, LDL-C, triglycerides, and adiponectin for the lipid node, and serum collagen propeptides for the ECM node. Each signature carries a different expected trajectory and monitoring window.
Why Does Node-Specific Biomarker Tracking Change What a Protocol Tracker Can Detect?
A single composite outcome such as body weight or HbA1c cannot distinguish which of semaglutide's three non-glycaemic pathway nodes is responding. Node-specific biomarkers allow a tracker to confirm that inflammatory, lipid, and ECM pathways are each responding on their expected timescales. A weight-loss response with absent inflammatory biomarker movement signals a different protocol adjustment than absent lipid biomarker movement.
The 2026 review synthesises proteomic and metabolomic datasets, principally Maretty and colleagues (Nature Medicine, 2025), who profiled 1,463 circulating proteins in STEP 1 and STEP 2 trial participants. This established that semaglutide's clinical outcomes are the aggregate output of simultaneous perturbations across multiple pathway clusters. Each cluster has identifiable circulating markers that change on distinct timescales.
For protocol designers, this matters because companion compounds are typically selected to augment a specific pathway node. If the target node is not responding as indicated by its biomarker signature, the rationale for the companion compound collapses regardless of whether the primary outcome is moving. Node-specific tracking is therefore a prerequisite for rational stack adjustment decisions.
The practical implication is that a protocol tracker built around semaglutide requires at minimum three independent biomarker panels, each with its own expected trajectory and non-response threshold. A single-panel tracker conflates three mechanistically distinct response questions into one undifferentiated signal.
What Are the Inflammatory Node Biomarkers, and What Trajectories Should a Tracker Expect?
The inflammatory node's primary tracking biomarkers are hsCRP and IL-6. Plutzky and colleagues (SELECT trial, Circulation 2026) documented hsCRP reductions of 12% at week 4, 19% at week 8, and 37.8% at week 104 in semaglutide-treated participants. These reductions were weight-independent, confirming direct GLP-1R-mediated NF-kB suppression.
The weight-independence of the hsCRP signal is the most protocol-relevant finding. In the SELECT Circulation 2026 analysis, hsCRP reductions were consistent across subgroups stratified by weight-loss magnitude, including participants who lost less than 5% body weight. This means a tracker can use hsCRP trajectory as a direct inflammatory node response indicator without adjusting for concurrent weight change.
IL-6 is a secondary inflammatory node marker and a direct downstream output of NF-kB transcriptional activity. It is suppressed by semaglutide in parallel with hsCRP, though its trajectory data are less precisely characterised across the major RCTs. The Maretty 2025 proteomic dataset identified IL-6 pathway proteins among the significantly altered circulating proteins in STEP 1 and STEP 2 participants.
A non-response pattern at the inflammatory node is defined as less than 10% hsCRP reduction by week 8. This may indicate insufficient GLP-1R occupancy, individual receptor-level variation, or a dominant inflammatory driver operating independently of NF-kB. Each interpretation carries a different protocol adjustment implication: dose titration, receptor sensitivity assessment, or companion compound addition targeting an alternative inflammatory pathway.
What Are the Lipid Node Biomarkers, and How Do Their Trajectories Differ From the Inflammatory Node?
The lipid node's primary tracking biomarkers are LDL-C, triglycerides, VLDL, and adiponectin. Berto-Junior and colleagues (MDPI, 2026) documented a 12% LDL reduction, 28.4% VLDL reduction, and 20% triglyceride reduction in semaglutide-treated participants. These lipid markers respond at weeks 12 to 24, reflecting the slower hepatic transcriptional mechanism.
The delayed lipid response reflects the mechanism. Hepatic de novo lipogenesis suppression requires AMPK-mediated phosphorylation of acetyl-CoA carboxylase and downstream SREBP-1c transcriptional suppression. This gene-expression-level change takes weeks to propagate into measurable lipid flux reduction, and VLDL secretion reduction follows hepatic lipogenic enzyme suppression with a further lag.
Adiponectin is the most mechanistically informative of the lipid node markers because it reflects adipose tissue secretome remodelling rather than hepatic lipid flux. The 2026 Abel and colleagues (PMC12898281) proteomic analysis confirmed that semaglutide remodels the adipose secretome in a pattern consistent with reduced lipotoxic signalling. An adiponectin increase without corresponding LDL or triglyceride reduction suggests adipose remodelling is proceeding while hepatic lipid flux remains unaffected, a node-level dissociation with direct implications for companion compound selection.
For protocol trackers, the lipid node panel should be assessed no earlier than week 12 and ideally at weeks 24 and 48. Assessing lipid biomarkers at week 4 will produce a false non-response signal for the lipid node, because the hepatic lipogenic mechanism has not yet had sufficient time to propagate to measurable circulating changes.
What Are the ECM Node Biomarkers, and Why Are They the Hardest to Track in a Running Protocol?
The ECM node's most accessible tracking biomarkers are serum PIIINP (procollagen type III N-terminal propeptide) and serum hyaluronic acid. Sanyal and colleagues (ESSENCE phase 3 trial, NEJM 2025) documented liver fibrosis improvement in approximately 37% of semaglutide-treated participants versus 22% on placebo at week 72. These serum markers are the only non-biopsy ECM proxy available.
The ECM node presents the most significant tracking challenge because its primary clinical endpoint, histological fibrosis regression, requires liver biopsy. Serum PIIINP and hyaluronic acid are validated surrogates for hepatic fibrosis in MASH populations, but their sensitivity to the more subtle ECM remodelling effects documented in islet tissue (Cardoso and colleagues, 2023) and adipose tissue (Abel and colleagues, 2026) is unknown.
Matrix metalloproteinase-9 (MMP-9) is a candidate ECM node marker with a distinct mechanistic basis. MMP-9 is the primary collagenolytic enzyme responsible for degrading existing fibrous ECM, and its activity is modulated by GLP-1R signalling in hepatic stellate cells. However, MMP-9 is not routinely measured in clinical practice, and its trajectory under semaglutide treatment has not been systematically characterised in a large RCT.
For protocol trackers, the ECM node panel is best treated as a late-protocol assessment at week 48 or beyond, using serum PIIINP and hyaluronic acid as the most accessible proxies. Protocols shorter than 24 weeks are unlikely to produce detectable ECM node biomarker movement, and assessing this panel in short-cycle stacks will generate uninformative data.
How Should a Protocol Tracker Interpret Node-Specific Non-Response Patterns for Stack Adjustment?
Node-specific non-response patterns carry distinct stack adjustment implications. Absent inflammatory node response (hsCRP below 10% reduction by week 8) points to receptor-level variation or a dominant non-NF-kB driver. Absent lipid node response by week 24 points to hepatic lipogenic pathway resistance. Absent ECM node response at week 72 is the least actionable finding in a running protocol.
The inflammatory non-response pattern is the most immediately actionable. If hsCRP is not moving by week 8 despite adequate semaglutide dosing, the NF-kB suppression axis is either not engaging or is being overridden by a dominant upstream inflammatory signal. In this scenario, a companion compound targeting an alternative anti-inflammatory pathway such as thymosin alpha-1's TLR-dependent immune modulation may address a pathway that semaglutide's GLP-1R mechanism is not reaching.
The lipid non-response pattern at week 24 requires distinguishing between hepatic and adipose components. If adiponectin is rising but LDL-C and triglycerides are not moving, the dissociation suggests the hepatic lipogenic pathway is resistant to GLP-1R-mediated suppression in this individual. Companion compounds targeting hepatic lipid metabolism through non-GLP-1R mechanisms such as tesamorelin's GH-axis-driven hepatic fat reduction may address the specific unresponsive component.
The ECM non-response pattern at week 72 is the least actionable because the interaction classification for all ECM-targeting peptide pairings with semaglutide remains Interaction Unknown. No co-administration trial has demonstrated additive ECM benefit for any companion compound. Protocol designers should document ECM non-response as a data point for future protocol intelligence rather than as an immediate trigger for stack modification.
Stack Blueprint: Node-Specific Biomarker Tracker for Semaglutide Protocols
The 2026 systems medicine review's molecular data translate into a three-panel biomarker tracker with node-specific assessment windows, expected trajectory ranges, non-response thresholds, and stack adjustment decision logic. Each panel is assessed independently. A response at one node does not predict response at another, and a non-response at one node does not indicate overall protocol failure.
| Node | Primary Biomarkers | Assessment Window | Expected Trajectory | Non-Response Threshold | Non-Response Interpretation | Stack Adjustment Signal | Interaction Class |
|---|---|---|---|---|---|---|---|
| Inflammatory Node | hsCRP, IL-6 | Weeks 4, 8, 26 | hsCRP -12% by week 4; -19% by week 8; -37.8% by week 104 (SELECT, Plutzky 2026) | Less than 10% hsCRP reduction by week 8 | Insufficient GLP-1R occupancy; dominant non-NF-kB inflammatory driver; individual receptor variation | Assess dose titration; consider thymosin alpha-1 for non-overlapping TLR-pathway anti-inflammatory coverage |
Proposed Co-Activity (no co-administration RCT) |
| Lipid Node | LDL-C, triglycerides, VLDL, adiponectin | Weeks 12, 24, 48 | LDL -12%; VLDL -28.4%; TG -20%; adiponectin +20 to 45% (Berto-Junior 2026; Abel 2026) | LDL-C and TG unchanged by week 24 | Hepatic lipogenic pathway resistance; adipose-hepatic dissociation if adiponectin rises without LDL/TG movement | Dissociation pattern: consider tesamorelin for GH-axis hepatic fat reduction if hepatic component non-responsive |
Single-Compound Extrapolation (no co-administration RCT) |
| ECM Node | Serum PIIINP, hyaluronic acid, MMP-9 (research use) | Weeks 48, 72 | Fibrosis regression approximately 37% vs approximately 22% placebo at week 72 (ESSENCE, Sanyal 2025); serum ECM marker trajectories not precisely characterised in non-MASH populations | No PIIINP or hyaluronic acid reduction by week 72 | ECM remodelling not proceeding; may reflect non-MASH population; insufficient protocol duration | Document as data point; no validated companion compound with demonstrated additive ECM benefit in co-administration with semaglutide |
Interaction Unknown |
| Glycaemic / Incretin Node (reference) | HbA1c, fasting glucose, body weight | Weeks 12, 26, 52 | HbA1c -1.5 to 2.0%; body weight -10 to 15% (STEP 1 to 4; SUSTAIN 1 to 10) | HbA1c reduction below 0.5% by week 26 in T2D context | Inadequate dose; adherence gap; GLP-1R downregulation; competing hyperglycaemic driver | Dose titration; adherence review; secretagogue hypoglycaemia risk if co-administered, dose adjustment required immediately | Co-Administration Data (secretagogue pairings) |
What Are the Critical Data Gaps That Limit This Biomarker Tracking Framework in 2026?
Three data gaps constrain this framework: no proteomic timecourse study has tracked the Maretty-identified biomarker changes at multiple intermediate timepoints in a non-MASH, non-T2D population; serum ECM markers have not been validated as ECM node response proxies in non-fibrotic populations; and no co-administration trial has tested whether companion compound addition produces detectable biomarker changes at any specific node.
The population-specificity gap is the most consequential for self-experimenters. The hsCRP trajectory data from SELECT derive from a cardiovascular disease population. The lipid biomarker data from Berto-Junior and colleagues (2026) and Abel and colleagues (2026) derive from T2D and obesity populations respectively.
Whether these trajectories generalise to metabolically healthier individuals using semaglutide for body composition purposes is an open empirical question. No proteomic timecourse study has been conducted in a non-disease population, and the expected biomarker magnitudes may differ substantially from the tracker values above.
The intermediate timepoint gap limits the precision of non-response thresholds. The SELECT Circulation 2026 analysis provides hsCRP data at weeks 4, 8, and 104 but not at weeks 12, 24, or 52. Non-response thresholds in the tracker above are therefore derived from the available anchor points, not from a continuous trajectory model.
The co-administration gap is the most structurally limiting. The entire biomarker tracking framework assumes that companion compound effects on a given node will be detectable as deviations from the expected semaglutide monotherapy trajectory. Without a co-administration trial establishing what that deviation looks like, the tracker can confirm node-level semaglutide response but cannot attribute deviations to companion compound activity with confidence.
For related protocol intelligence on the static interaction node map, see What Does the 2026 Systems Medicine View of Semaglutide Reveal About Its Inflammatory, Lipid, and ECM Interaction Nodes for Protocol Designers? For the temporal sequencing framework, see When Does Each Semaglutide Pathway Node Activate and What Does the 2026 Systems Medicine Review Mean for Companion-Compound Timing in Protocol Design? For the therapeutic protocol and safety context, see What Does 2026 Research Reveal About the Systems Medicine View of Semaglutide: From Clinical Trials to Molecular Mechanisms? on Peptides Plus. What Does the 2026 Systems Medicine View of Semaglutide Reveal About Its Inflammatory, Lipid, and ECM Pathways? What Does 2026 Research Reveal About the Systems Medicine View of Semaglutide: From Clinical Trials to Molecular Mechanisms? What Does the 2026 Systems Medicine Multi-Omics Data on Semaglutide Reveal About Cross-Tissue Substrate Flux and Diet Timing?